keyword
https://read.qxmd.com/read/38648056/prevalence-of-homologous-recombination-deficiency-among-patients-with-germline-rad51c-d-breast-or-ovarian-cancer
#1
JOURNAL ARTICLE
Sara Torres-Esquius, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Marcel Romey, Àlex Teulé, Gemma Llort, Ana Herrero, Pilar Sánchez-Henarejos, Anna Vallmajó, Santiago González-Santiago, Isabel Chirivella, Juana Maria Cano, Begoña Graña, Sara Simonetti, Isabela Díaz de Corcuera, Teresa Ramon Y Cajal, Judit Sanz, Sara Serrano, Andrea Otero, Cristina Churruca, Ana Beatriz Sánchez-Heras, Sonia Servitja, Carmen Guillén-Ponce, Joan Brunet, Carsten Denkert, Violeta Serra, Judith Balmaña
IMPORTANCE: RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival. OBJECTIVE: To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38647725/the-ras-related-protein-rab22a-interacts-with-hypoxia-inducible-factor-1-alpha-hif-1%C3%AE-in-mda-mb-231-breast-cancer-cells-in-hypoxia
#2
JOURNAL ARTICLE
Nikolaos A Papanikolaou, Maria Kakavoulia, Christos Ladias, Athanasios G Papavassiliou
BACKGROUND: Recent studies suggest that hypoxia-inducible factor 1-alpha (HIF-1α) and the small GTPase protein Ras-related protein Rab-22 A (RAB22A) may be colocalized in the cytoplasm and that as a conequence they may enhance the formation of microvesicles in breast cancer cells under hypoxia. Therefore, we sought to determine whether these two proteins are present in intracellular complexes in breast carcinoma cells. METHODS AND RESULTS: Evaluation using molecular docking indicated that HIF-1α and RAB22A interact with each other...
April 22, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38647255/trps1-is-a-highly-sensitive-marker-for-breast-cancer-a-tissue-microarray-study-evaluating-more-than-19-000-tumors-from-152-different-tumor-entities
#3
JOURNAL ARTICLE
Maximilian Lennartz, Neele Löhr, Doris Höflmayer, Sebastian Dwertmann Rico, Clara von Bargen, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Veit Bertram, Christoph Fraune, Natalia Gorbokon, Sören Weidemann, Niclas C Blessin, Claudia Hube-Magg, Anne Menz, Ria Schlichter, Till Krech, Andrea Hinsch, Eike Burandt, Guido Sauter, Ronald Simon, Martina Kluth, Andreas H Marx, Patrick Lebok, David Dum, Sarah Minner, Frank Jacobsen, Till S Clauditz, Christian Bernreuther, Stefan Steurer
Trichorhinophalangeal syndrome 1 (TRPS1) is a nuclear protein highly expressed in breast epithelial cells. TRPS1 immunohistochemistry (IHC) has been suggested as a breast cancer marker. To determine the diagnostic and prognostic utility of TRPS1 IHC, tissue microarrays containing 19,201 samples from 152 different tumor types and subtypes were analyzed. GATA3 IHC was performed in a previous study. TRPS1 staining was seen in 86 of 152 tumor categories with 36 containing at least one strongly positive case. TRPS1 staining predominated in various types of breast carcinomas (51%-100%), soft tissue tumors (up to 100%), salivary gland tumors (up to 46%), squamous cell carcinomas (up to 35%), and gynecological cancers (up to 40%)...
April 22, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38646723/-68-ga-labeled-epha2-targeted-cyclic-peptide-a-novel-positron-imaging-tracer-for-triple-negative-breast-cancer
#4
JOURNAL ARTICLE
Bin Qu, Xianjun Li, Yuze Ma, Yanzhi Wang, Yeming Han, Guihua Hou, Feng Gao
The absence of better biomarkers currently limits early diagnosis and treatment of triple-negative breast cancer (TNBC). Our previously published study reported that the cyclic-peptide SD01 exhibited specific binding to EphA2 (Ephrin type-A receptor 2) on TNBC. To develop a novel PET imaging agent, we prepared gallium-68 (68 Ga) labeled-DOTA-SD01 and evaluated its specificity and effectiveness through micro PET/CT imaging in a TNBC-bearing mouse model. SD01 and a control linear peptide YSA were conjugated to DOTA and subsequently labeled with 68 Ga, obtaining 68 Ga-DOTA-SD01 and 68 Ga-DOTA-YSA...
April 22, 2024: Dalton Transactions: An International Journal of Inorganic Chemistry
https://read.qxmd.com/read/38646672/inhibition-of-cdk7-mitigates-doxorubicin-cardiotoxicity-and-enhances-anticancer-efficacy
#5
JOURNAL ARTICLE
Jingrui Chen, Jing Wei, Peng Xia, Yuening Liu, Mahder Dawit Belew, Ryan Toohill, Boyang Jason Wu, Zhaokang Cheng
AIMS: The anthracycline family of anticancer agents such as doxorubicin (DOX) can induce apoptotic death of cardiomyocytes and cause cardiotoxicity. We previously reported that DOX-induced apoptosis is accompanied by cardiomyocyte cell cycle-reentry. Cell cycle progression requires cyclin-dependent kinase 7 (CDK7)-mediated activation of downstream cell cycle CDKs. This study aims to determine whether CDK7 can be targeted for cardioprotection during anthracycline chemotherapy. METHODS AND RESULTS: DOX exposure induced CDK7 activation in mouse heart and isolated cardiomyocytes...
April 22, 2024: Cardiovascular Research
https://read.qxmd.com/read/38646654/the-hsp90-inhibitor-hvh-2930-exhibits-potent-efficacy-against-trastuzumab-resistant-her2-positive-breast-cancer
#6
JOURNAL ARTICLE
Minsu Park, Eunsun Jung, Jung Min Park, Soeun Park, Dongmi Ko, Juyeon Seo, Seongjae Kim, Kee Dal Nam, Yong Koo Kang, Lee Farrand, Van-Hai Hoang, Cong-Truong Nguyen, Minh Thanh La, Gibeom Nam, Hyun-Ju Park, Jihyae Ann, Jeewoo Lee, Yoon-Jae Kim, Ji Young Kim, Jae Hong Seo
Rationale: Resistance to targeted therapies like trastuzumab remains a critical challenge for HER2-positive breast cancer patients. Despite the progress of several N-terminal HSP90 inhibitors in clinical trials, none have achieved approval for clinical use, primarily due to issues such as induction of the heat shock response (HSR), off-target effects, and unfavorable toxicity profiles. We sought to examine the effects of HVH-2930, a novel C-terminal HSP90 inhibitor, in overcoming trastuzumab resistance. Methods: The effect of HVH-2930 on trastuzumab-sensitive and -resistant cell lines in vitro was evaluated in terms of cell viability, expression of HSP90 client proteins, and impact on cancer stem cells...
2024: Theranostics
https://read.qxmd.com/read/38646527/the-functional-role-of-l-fucose-on-dendritic-cell-function-and-polarization
#7
JOURNAL ARTICLE
Chase Burton, Amirreza Bitaraf, Kara Snyder, Chaomei Zhang, Sean J Yoder, Dorina Avram, Dongliang Du, Xiaoqing Yu, Eric K Lau
Despite significant advances in the development and refinement of immunotherapies administered to combat cancer over the past decades, a number of barriers continue to limit their efficacy. One significant clinical barrier is the inability to mount initial immune responses towards the tumor. As dendritic cells are central initiators of immune responses in the body, the elucidation of mechanisms that can be therapeutically leveraged to enhance their functions to drive anti-tumor immune responses is urgently needed...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38646501/progress-in-cancer-research-on-the-regulator-of-phagocytosis-cd47-which-determines-the-fate-of-tumor-cells-review
#8
REVIEW
Fan Wu, Hongyuan Pang, Fan Li, Mengqing Hua, Chuanwang Song, Jie Tang
Cluster of differentiation 47 (CD47) is a transmembrane protein that is widely and moderately expressed on the surface of various cells and can have an essential role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis and other related responses by binding to its ligands, integrins, thrombospondin-1 and signal regulatory protein α. The poor prognosis of cancer patients is closely associated with high expression of CD47 in glioblastoma, ovarian cancer, breast cancer, bladder cancer, colon cancer and hepatocellular carcinoma...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646426/targeting-estrogen-mediated-cyp4f2-cyp4f11-20-hete-metabolic-disorder-decelerates-tumorigenesis-in-er-breast-cancer
#9
JOURNAL ARTICLE
Juan Yang, Yin Li, Xiao Han, Tianjiao Li, Ding Li, Qiao Liu, Lizhong Yan, Fei Li, Xiaolin Pei, Ya Feng, Zhoujun Lin, Zhenkun Fu, Changjun Wang, Qiang Sun, Chenggang Li
PURPOSE: As the most common subset of breast cancer (BC), estrogen receptor positive (ER+) BC accounting for 80% of cases, has become a global public health concern. The female hormone estrogen (E2) unequivocally drives ER + breast malignancies. The reasons that estrogen affects BC development has long been considered, yet further study remains to be conducted of the molecular events in the E2-estrogen receptor α (ERα) signaling pathway in ER + BC progression, especially lipid metabolism, so providing more options for tailored and individualized therapy...
July 2024: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/38646373/a-rare-and-intriguing-case-report-of-metaplastic-breast-carcinoma
#10
Vallal Kani, Vimal Chander, Sulochana Sonti, Sridevi Manian, Sudha Vasudevan, Muthuvel Esakki, Sarah Grace Priyadarshini, Karthika Rajendran
Metaplastic breast carcinoma (MBC) is a rare and aggressive subtype of breast cancer characterized by the presence of both epithelial and mesenchymal components within the tumor. Its clinical and radiological appearance is comparable to other types of breast cancer, but it grows rapidly. The diagnosis of metaplastic carcinoma is largely based on the epithelial origin of the cells confirmed by immunohistochemistry (IHC). Compared to invasive ductal carcinoma, metaplastic carcinoma has a worse overall survival rate...
March 2024: Curēus
https://read.qxmd.com/read/38646326/computational-analysis-of-single-nucleotide-polymorphisms-in-human-hic1-gene
#11
JOURNAL ARTICLE
Arora Annanya, Boopathi Priyadharshini, Vasugi Suresh, Elangovan Dilipan
Background A putative tumor suppressor gene called HIC1 (hypermethylated in cancer) is situated at 17p13.3, a locus where the allelic loss occurs often in human malignancies, including breast cancer. Hypermethylated in cancer 1 protein is a protein that in humans is encoded by the HIC1 gene and it's a  Homo sapiens  (Human). This gene functions as a growth regulatory and tumor repressor gene. The molecular function of HIC1 gene includes DNA-binding transcription factor activity, sequence-specific DNA binding, DNA binding, histone deacetylase binding, protein binding, metal ion binding, nucleic acid binding, DNA-binding transcription repressor activity, RNA polymerase II-specific, DNA-binding transcription factor activity, RNA polymerase II-specific...
March 2024: Curēus
https://read.qxmd.com/read/38645566/retraction-case-report-a-rare-case-of-tumor-to-tumor-metastasis-metastatic-lobular-breast-carcinoma-to-clear-cell-renal-cell-carcinoma
#12
(no author information available yet)
[This retracts the article DOI: 10.3389/pore.2023.1611204.].
2024: Pathology Oncology Research: POR
https://read.qxmd.com/read/38645515/construction-of-glutathione-responsive-paclitaxel-prodrug-nanoparticles-for-image-guided-targeted-delivery-and-breast-cancer-therapy
#13
JOURNAL ARTICLE
Weiwei Ma, Qiufeng Zhao, Shilong Zhu, Xinyue Wang, Chuangchuang Zhang, Daming Ma, Na Li, Yanyan Yin
Paclitaxel (PTX) remains an essential drug in the treatment of breast cancer. To improve metabolic stability and real-time monitoring of drug location, we develop a visualized nano-prodrug. Novel hyaluronic acid (HA)-coated glutathione (GSH)-sensitive chitosan (CS)-based nano-prodrug (HA/TPE-CS-SS-PTX NPs) with aggregation-induced emission effects (AIE) were accomplished. The prodrug NPs (drug loading 29.32%, particle size 105 nm, regular sphericity) exhibit excellent fluorescence stability. The prodrug NPs could target tumor cells with high expression of CD44 and decompose in the presence of high concentrations of glutathione...
April 16, 2024: RSC Advances
https://read.qxmd.com/read/38645485/tmbcalc-a-computational-pipeline-for-identifying-pan-cancer-tumor-mutational-burden-gene-signatures
#14
JOURNAL ARTICLE
Grete Francesca Privitera, Salvatore Alaimo, Anna Caruso, Alfredo Ferro, Stefano Forte, Alfredo Pulvirenti
BACKGROUND: In the precision medicine era, identifying predictive factors to select patients most likely to benefit from treatment with immunological agents is a crucial and open challenge in oncology. METHODS: This paper presents a pan-cancer analysis of Tumor Mutational Burden (TMB). We developed a novel computational pipeline, TMBcalc, to calculate the TMB. Our methodology can identify small and reliable gene signatures to estimate TMB from custom targeted-sequencing panels...
2024: Frontiers in Genetics
https://read.qxmd.com/read/38645412/link-a-unveiling-its-functional-role-and-clinical-significance-in-human-tumors
#15
REVIEW
Bing Liao, Jialing Wang, Yilin Xie, Hongliang Luo, Jun Min
LINK-A, also recognized as LINC01139, has emerged as a key oncological lncRNA in cancer. LINK-A is upregulated in solid and liquid tumor samples, including breast cancer, ovarian cancer, glioma, non-small-cell lung cancer, and mantle cell lymphoma. Notably, LINK-A is involved in regulating critical cancer-related pathways, such as AKT and HIF1α signaling, and is implicated in a range of oncogenic activities, including cell proliferation, apoptosis, epithelial-mesenchymal transition (EMT), cell invasion and migration, and glycolysis reprogramming...
2024: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/38645250/expression-of-c-erb-b2-oncoprotein-as-a-neoantigen-strategy-to-repurpose-anti-neu-antibody-therapy-in-a-model-of-melanoma
#16
Emmanuel M Gabriel, Brian Necela, Deborah Bahr, Sneha Vivekanandhan, Barath Shreeder, Sanjay Bagaria, Keith L Knutson
In this study, we tested a novel approach of "repurposing" a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies are readily available. We constructed a lentivirus encoding c-erb-B2 (the animal homolog to HER2/neu). This was used to transfect B16 melanoma in vitro for use in an orthotopic preclinical mouse model, which resulted in expression of c-erb-B2 as a neoantigen target for anti-c-erb-B2 monoclonal antibody (7...
April 3, 2024: Research Square
https://read.qxmd.com/read/38645153/role-of-numa1-in%C3%A2-breast-cancer-stem-cells-with-implications-for-combination-therapy-of-pim1-and-autophagy-inhibition-in-triple-negative-breast-cancer
#17
Kanakaraju Manupati, Mingang Hao, Michael Haas, Syn Kok Yeo, Jun-Lin Guan
BACKGROUND: Nuclear mitotic apparatus protein 1 (NuMA1) is a cell cycle protein and upregulated in breast cancer. However, the role of NuMA1 in TNBC and its regulation in heterogenous populations remains elusive. METHODS: We performed CRISPR mediated deletion of NuMA1 in mouse TNBC cells, BF3M. FACS was utilized to isolate BCSCs, and bulk cells based on CD29 and CD61 markers. Cell viability, migration, and invasion ability of BCSCs and bulk cells was evaluated using MTT, wound healing and transwell invasion assays, respectively...
April 1, 2024: Research Square
https://read.qxmd.com/read/38644978/estradiol-induces-bone-osteolysis-in-triple-negative-breast-cancer-via-its-membrane-associated-receptor-er%C3%AE-36
#18
JOURNAL ARTICLE
D Joshua Cohen, Cydney D Dennis, Jingyao Deng, Barbara D Boyan, Zvi Schwartz
Triple-negative breast cancer (TNBC) is thought to be an estradiol-independent, hormone therapy-resistant cancer because of lack of estrogen receptor alpha 66 (ERα66). We identified a membrane-bound splice variant, ERα36, in TNBC cells that responds to estrogen (E2 ) and may contribute to bone osteolysis. We demonstrated that the MDA-MB-231 TNBC cell line, which expresses ERα36 similarly to MCF7 cells, is responsive to E2 , forming osteolytic tumors in vivo. MDA-MB-231 cells activate osteoclasts in a paracrine manner...
May 2024: JBMR Plus
https://read.qxmd.com/read/38644364/tumor-growth-arrest-effect-of-tetrahydroquinazoline-derivative-human-topoisomerase-ii-alpha-inhibitor-in-hpv-negative-head-and-neck-squamous-cell-carcinoma
#19
JOURNAL ARTICLE
Patrizia Sarogni, Nicoletta Brindani, Agata Zamborlin, Alessandra Gonnelli, Michele Menicagli, Ana Katrina Mapanao, Federico Munafò, Marco De Vivo, Valerio Voliani
Oral malignancies continue to have severe morbidity with less than 50% long-term survival despite the advancement in the available therapies. There is a persisting demand for new approaches to establish more efficient strategies for their treatment. In this regard, the human topoisomerase II (topoII) enzyme is a validated chemotherapeutics target, as topoII regulates vital cellular processes such as DNA replication, transcription, recombination, and chromosome segregation in cells. TopoII inhibitors are currently used to treat some neoplasms such as breast and small cells lung carcinomas...
April 21, 2024: Scientific Reports
https://read.qxmd.com/read/38644310/-case-report-of-occult-breast-cancer-with-triple-negative-subtype
#20
JOURNAL ARTICLE
Yuko Tanaka, Yuki Ohshima, Yumi Fukaya, Keiko Hosoya, Makoto Wakahara
A 61-year-old woman presented at a nearby clinic with a complaint of a mass in the right axilla. Initial imaging examinations, including mammography, ultrasonography, and breast MRI, did not reveal any obvious intramammary lesions, although a swollen lymph node was observed in the right axilla. Fine-needle aspiration cytology confirmed malignancy. Hence, a core needle biopsy was performed. The results indicated a suspected metastasis of invasive ductal carcinoma(ER-, PgR-, HER2-); however, the primary tumor could not be definitively determined...
April 2024: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
31630
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.